

1           **Title: Prevalence of salivary anti-SARS-CoV-2 IgG antibodies in vaccinated children**

2  
3           **Author names and affiliations:** María Noel Badano, PhD<sup>a,b</sup>; Alejandra Duarte, PhD<sup>a\*</sup>; Gabriela  
4           Salamone, PhD<sup>a\*</sup>; Florencia Sabbione, PhD<sup>a</sup>, Matias Pereson, BSc<sup>c</sup>; Roberto Chuit, MD<sup>d</sup>;  
5           Patricia Baré, PhD<sup>a,b</sup>  
6  
7

8           Affiliations: <sup>a</sup>Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones  
9           Científicas y Técnicas (CONICET), Academia Nacional de Medicina. Postal address: J.A.  
10          Pacheco de Melo 3081, CABA 1425, Buenos Aires, Argentina; <sup>b</sup>Instituto de Investigaciones  
11          Hematológicas (IIHEMA), Academia Nacional de Medicina. Postal address: J.A. Pacheco de  
12          Melo 3081, CABA 1425, Buenos Aires, Argentina; <sup>c</sup>Instituto de Investigaciones en Bacteriología  
13          y Virología Molecular (IBaViM), Facultad de Farmacia y Bioquímica, Universidad de Buenos  
14          Aires. Junín 956, CABA CP 1113, Buenos Aires, Argentina; <sup>d</sup>Instituto de Investigaciones  
15          Epidemiológicas (IIE), Academia Nacional de Medicina. Postal address: J.A. Pacheco de Melo  
16          3081, CABA 1425, Buenos Aires, Argentina.  
17

18          \* Contributed equally to this research.  
19

20          **Address correspondence to:** María Noel Badano, Laboratorio de Patogenia de Infecciones  
21          Virales, Instituto de Medicina Experimental (IMEX)-CONICET, Academia Nacional de  
22          Medicina, J.A. Pacheco de Melo 3081, CABA 1425, [noebadano@yahoo.com.ar](mailto:noebadano@yahoo.com.ar),  
23          +5491167586135.  
24

25          **Short title:** Salivary SARS-CoV-2 antibodies in vaccinated children  
26

27          **Conflict of Interest Disclosures:** The authors declare that they have no known competing  
28          financial interests or personal relationships that could have appeared to influence the work  
29          reported in this paper.  
30

31          **Funding/Support:** This research received no external funding  
32          .  
33

34          **Abbreviations:** binding antibody units (BAU) per mL (BAU/mL), geometric mean  
35          concentrations (GMC), 95% confidence intervals (95% CI)  
36  
37  
38  
39

40

41

42

43 **Contributors Statement Page**

44

45 Drs María Noel Badano and Patrica Baré conceptualized and designed the study, coordinated and  
46 supervised data collection, measured antibody concentrations, performed statistical analysis,  
47 drafted the initial manuscript, and critically reviewed and revised the manuscript.

48

49 Drs Alejandra Duarte, Gabriela Salamone, Florencia Sabbione and BSc Matias Pereson designed  
50 the data collection instruments, collected samples and data, carried out the initial analyses, and  
51 critically reviewed and revised the manuscript.

52

53 Dr Roberto Chuit performed statistical analysis, critically reviewed and revised the manuscript.

54

55 All authors approved the final manuscript as submitted and agree to be accountable for all  
56 aspects of the work.

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74 **ABSTRACT**

75

76 Vaccination against COVID-19 has mitigated the impact of SARS-CoV-2 infection, decreasing  
77 the probability of progression to severe disease and death in vaccinated people.

78 Parallel to the development and administration of COVID-19 vaccines, the immune response  
79 induced by the different vaccine platforms has been investigated, mainly, in the adult population.

80 However, since the approval of the vaccines for use in pediatric individuals was a posteriori,  
81 vaccination began later in this population. This, added to the difficulty in obtaining blood  
82 samples from pediatric individuals, has led to less knowledge about the humoral immune  
83 response following vaccination in children.

84 In this work, we analyzed the humoral response induced by vaccination in children through a  
85 non-invasive approach such as the measurement of specific salivary antibodies. Our results  
86 showed a high prevalence of specific salivary antibodies (81%), with the highest levels of  
87 antibodies being observed in those children who had three doses, a greater number of exposures  
88 and a shorter interval time between the last exposure to SARS-CoV-2 antigens and saliva  
89 collection. These results agree with those reported for the systemic humoral immune response in  
90 vaccinated adults, suggesting the administration of booster doses in children to maintain high  
91 antibody levels.

92 Therefore, determination of salivary antibodies against SARS-CoV-2 could be a non-invasive  
93 tool for disease surveillance, vaccination follow-up and to assist vaccination strategies against  
94 COVID-19.

95

96

97 **INTRODUCTION**

98

99 Systemic humoral response following COVID-19 vaccination has been widely studied, while  
100 less attention had received salivary response. Reports showed specific salivary antibodies after  
101 vaccination with COVID-19 mRNA vaccines, which correlated with serum neutralization and  
102 indicated seroconversion.<sup>1,2</sup> However, most studies were conducted in adults with few studies  
103 about immune response following vaccination in children.<sup>3-5</sup>

104 In this study, we aimed to analyze the humoral response following vaccination in children,  
105 through a non-invasive approach like the measurement of specific salivary antibodies.

106

107

108 **METHODS**

109

110 Since March 2022, children younger than 18 years were recruited to analyze prevalence of  
111 salivary anti-SARS-CoV-2 IgG antibodies. IgG anti-spike antibody concentrations, in binding  
112 antibody units (BAU) per mL (BAU/mL), were determined by ELISA.<sup>6</sup> Statistical analyzes were  
113 performed with GraphPad Prism software. Geometric mean concentrations (GMC) of antibody  
114 levels with 95% confidence intervals (95% CI) were calculated. Antibody levels between groups  
115 were compared with Mann-Whitney test and between paired samples with Paired t test. Multiple  
116 linear regression was performed to analyze variables associated with antibody levels. Statistical  
117 significance was defined as a 2-tailed  $p < 0.05$ . Supplemental information includes other  
118 experimental methods. This study was approved by the Academia Nacional de Medicina Ethics  
119 Committee. Written informed consent was obtained from parents.

120 **RESULTS**

121

122 Saliva samples were collected from 89 children (Median age: 10 (4–17); 47/89 (52%): male)

123 including unvaccinated (n=1), with one (n=2), two (n=52) and three (n=34) vaccine doses (Table

124 1). Fourteen subjects had a confirmed past SARS-CoV-2 infection, 39 were household contacts

125 and 36 were unexposed subjects. Median time between last exposure to SARS-CoV-2 antigens

126 (through vaccination, infection or exposure) and saliva collection was 77 (21–270) days.

127 Prevalence of SARS-CoV-2 spike-specific IgG antibodies in total samples was 81% (72/89),

128 73% (38/52) in children with two vaccine doses and 97% (33/34) in those with three doses.

129 Higher antibody concentrations were observed in subjects receiving three doses compared to

130 those receiving two (GMC: 834.0 IU/ml, 95% CI: 456.6–1523 vs GMC: 32.7 IU/ml, 95% CI:

131 17.0–63.1;  $p < 0.0001$ ) (Figure 1A), showing highest levels those with heterologous third doses,

132 who received two doses of Sinopharm vaccine and mRNA vaccines as third doses (GMC: 1997

133 IU/ml, 95% CI: 878.6–4538;  $p < 0.01$ ). Antibody concentrations increased with a greater number

134 of exposures (through vaccination, infection or exposure) (Figure 1B). Subjects with a longer

135 interval time between last exposure and saliva collection had lower antibody concentrations than

136 those with a shorter interval time (GMC: 28.4 IU/ml, 95% CI: 12.9–62.6 vs GMC: 301.3 IU/ml,

137 95% CI: 147.9–613.8;  $p < 0.0001$ ) (Figure 1C). During follow-up, eight children who had two

138 doses became infected (n=2) or were household contacts (n=6), showing an increase in antibody

139 concentrations after exposure ( $p < 0.01$ ) (Figure 1D). Number of vaccine doses ( $\beta_1$ : 2314, 95%

140 CI: 1093-3536;  $p < 0.001$ ) and symptomatic exposure ( $\beta_2$ : 1355, 95% CI: 340.4–2369;  $p < 0.01$ ),

141 were associated with antibody levels in a multivariable linear regression analysis ( $p < 0.0001$ ).

142

143 **DISCUSSION**

144

145 Vaccination progressed more quickly in adults, leading to less knowledge about the immune  
146 response following vaccination in children. In this study, we observed a high salivary antibody  
147 prevalence (81%), detecting antibodies even in children whose last contact with SARS-CoV-2  
148 antigens had been 270 days before sample collection. However, higher antibody levels were  
149 observed in children who had: three doses, a greater number of exposures and a shorter interval  
150 time between last antigens exposure and saliva collection. These results agree with those  
151 reported for the systemic humoral response in vaccinated adults, suggesting booster doses in  
152 children to maintain high antibody levels.

153 Limitations include lack of information on neutralizing and specific IgA antibody responses.

154 Though, we did not have saliva-blood sample pairs for all individuals, our preliminary results in  
155 vaccinated adults show a positive correlation between specific salivary and blood antibodies.

156 Determination of salivary antibodies against SARS-CoV-2 could be a non-invasive tool for  
157 disease surveillance, vaccination follow-up and to assist vaccination strategies against COVID-  
158 19.

## Acknowledgments

The authors thank all the children enrolled in this study and their parents for their participation and collaboration. Some aspects of this work could not have been fulfilled without the generous contribution of the IIHEMA, IIE and Academia Nacional de Medicina who provide financial support to our ongoing research.

## References

1. Ketas TJ, Chaturbhuj D, Portillo VMC, et al. Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. *Pathog Immun.* 2021;6(1):116-134. doi: 10.20411/pai.v6i1.441.
2. Healy K, Pin E, Chen P, et al. Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals. *Med (N Y).* 2022;3(2):137-153.e3. doi: 10.1016/j.medj.2022.01.001.
3. Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. *N Engl J Med.* 2022;386(1):35-46. doi: 10.1056/NEJMoa2116298.
4. Frenck RW Jr, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. *N Engl J Med.* 2021;385(3):239-250. doi: 10.1056/NEJMoa2107456.
5. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. *Lancet Infect Dis.* 2022;22(2):196-208. doi: 10.1016/S1473-3099(21)00462-X.
6. Badano MN, Sabbione F, Keitelman I, et al. Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2. *Mol Immunol.* 2022;143:94-99. doi: 10.1016/j.molimm.2022.01.009.

**Table 1. Characteristics of the study children**

	<b>Total subjects (n=89)</b>
<b>General characteristics</b>	
Age, median (range), y	10 (4–17)
Sex	
Female, No. (%)	42/89 (48)
Male, No. (%)	47/89 (52)
<b>Exposure to SARS-CoV-2</b>	
Unexposed, No. (%)	36/89 (40)
Confirmed past SARS-CoV-2 infection, No. (%)	14/89 (16)
Household contacts, No. (%)	39/89 (44)
Exposed children with COVID-19 compatible symptoms, No. (%)	30/53 (57)
<b>Vaccine schedules</b>	
Unvaccinated, No. (%)	1/89 (1)
<b>One dose</b>	
BBIBP-CorV, No. (%)	2/89 (2)
<b>Two doses</b>	
BBIBP-CorV x 2, No. (%)	46/89 (52)
BNT162b2 mRNA x 2, No. (%)	5/89 (6)
mRNA-1273 x 2, No. (%)	1/89 (1)
<b>Three doses</b>	
BNT162b2 mRNA x 3, No. (%)	17/89 (19)
BNT162b2 mRNA x 2 + mRNA-1273 x 1, No. (%)	4/89 (4)
BBIBP-CorV x 2 + BNT162b2 mRNA x1, No. (%)	11/89 (12)
BBIBP-CorV x 2 + mRNA-1273 x 1, No. (%)	2/89 (2)
Time between most recent antigen exposure and sample collection, median (range), days	77 (21–270)


BBIBP-CorV (Sinopharm); BNT162b2 mRNA (Pfizer–BioNTech); mRNA-1273 (Moderna).




## Figure legends

**Figure 1.** Salivary anti-SARS-CoV-2 antibodies were compared between children with two or three vaccine doses (A), different number of exposures (B), different time between last exposure and sample collection (C), before and after exposure in children with two doses (D). Assay detection limit (dotted lines) and GMC with 95% CI are shown.


A



B



C



D

